Tag Archive for: CAR-T

Astraveus opens path to accessible cell therapies with first ever end-to-end microfluidic CAR-T production

Paris, France, 9 January 2025 – Astraveus SAS (“Astraveus” or the “Company”), the Benchtop Cell Factory company, today announces the first ever successful end-to-end production of CAR-T cells within a microfluidic benchtop system. Using its fully automated Lakhesys Benchtop Cell FactoryTM, Astraveus has been able to demonstrate the potential of its unique microfluidic cell therapy processing […]

Leucid Bio to Participate in Upcoming Healthcare Conferences

London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November: BIO-Europe at Messe […]

Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011

Company on-track to dose first patient in LEU011 Phase 1/2 AERIAL trial during the fourth quarter of 2023 Lead programme, LEU011 previously awarded an Innovation Passport by MHRA for the treatment of solid tumours expressing NKG2D ligands London, UK – 21 September 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing […]

Changing the way we see CAR-T – Building out, not down

Co-founder and Chief Scientific Officer at Leucid Bio, Dr John Maher is revolutionising Chimeric Antigen Receptor (CAR) T-cell therapy, by designing CARs that are more powerful than predecessors and tough enough to tackle solid tumours. Dr Maher began his academic career at Trinity College, Dublin and has held numerous clinical, research and teaching positions at […]

Leucid Bio provides business update and outlook for 2023

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]